Nucleolipid Acid-Based Nanocarriers Restore Neuronal Lysosomal Acidification Defects

Area of Science:

• Neuroscience
• Biochemistry
• Nanotechnology

Background:

• Lysosomal dysfunction and elevated pH are implicated in neurodegenerative diseases like Parkinson's.
• Targeting lysosomal pH is a promising therapeutic strategy for neurodegeneration.
• The Blood-Brain Barrier (BBB) presents a significant challenge for CNS drug delivery.

Purpose of the Study:

• To design and synthesize novel nanocarriers for targeting lysosomal pH.
• To overcome the BBB challenge for effective CNS drug delivery.
• To evaluate the efficacy and safety of these nanocarriers in a Parkinson's disease model.

Main Methods:

• Conception and synthesis of DNA derivative-based nucleolipid nanocarriers.
• Incorporation of nucleolipids into an oil-in-water nanoemulsion vehicle.
• Biological assays on a genetic cell model of Parkinson's disease.

Main Results:

• Nucleolipid nanocarriers successfully crossed biological membranes.
• The nanocarriers effectively released acidic components to restore lysosomal pH.
• Assays confirmed non-toxicity and full restoration of lysosomal acidity at 40 µM in a Parkinson's disease cell model.

Conclusions:

• Novel nucleolipid nanocarriers offer a promising approach for treating neurodegenerative diseases.
• These nanocarriers can effectively cross the BBB and restore lysosomal function.
• The developed prodrugs demonstrate therapeutic potential for Parkinson's disease by normalizing lysosomal pH.